- Sales revenue continues its positive trend in third quarter
- 2019 guidance raised after year-on-year doubling of sales revenue
- Supply of GMP-quality Amanitin to partners established
- Schedule clarified for HDP-101 (BCMA-ATAC)
- Progress made by partners Link Health and Telix triggered milestone payments
- Further research grant received to continue MAGICBULLET EU project
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2019
Heidelberg Pharma AG today reported on the first nine months of fiscal year 2019 (1 December 2018 – 31 August 2019) and the Group’s financial figures.